In Vivo CRISPR Gene Editing in Patients with Herpetic Stromal Keratitis.

Anji Wei,Di Yin,Zimeng Zhai,Sikai Ling,Huangying Le,Lijia Tian,Jianjiang Xu,Soren R. Paludan,Yujia Cai,Jiaxu Hong
DOI: https://doi.org/10.1016/j.ymthe.2023.08.021
IF: 12.91
2023-01-01
Molecular Therapy
Abstract:In vivo CRISPR gene therapy holds large clinical potential, but the safety and efficacy remain largely unknown. Here, we injected a single dose of herpes simplex virus 1 (HSV-1)-targeting CRISPR formulation in the cornea of three patients with severe refractory herpetic stromal keratitis (HSK) during corneal transplantation. Our study is an investigator-initiated, open-label, single-arm, non-randomized interventional trial at a single center (NCT04560790). We found neither detectable CRISPR-induced off-target cleavages by GUIDE-seq nor systemic adverse events for 18 months on average in all three patients. The HSV-1 remained undetectable during the study. Our preliminary clinical results suggest that in vivo gene editing targeting the HSV-1 genome holds acceptable safety as a potential therapy for HSK.
What problem does this paper attempt to address?